[go: up one dir, main page]

SG11202003652QA - Anti-galectin-9 antibodies and uses thereof - Google Patents

Anti-galectin-9 antibodies and uses thereof

Info

Publication number
SG11202003652QA
SG11202003652QA SG11202003652QA SG11202003652QA SG11202003652QA SG 11202003652Q A SG11202003652Q A SG 11202003652QA SG 11202003652Q A SG11202003652Q A SG 11202003652QA SG 11202003652Q A SG11202003652Q A SG 11202003652QA SG 11202003652Q A SG11202003652Q A SG 11202003652QA
Authority
SG
Singapore
Prior art keywords
galectin
antibodies
Prior art date
Application number
SG11202003652QA
Other languages
English (en)
Inventor
Shohei Koide
George Miller
Akiko Koide
Linxiao Chen
Aleksandra Filipovic
Eric Elenko
Joseph Bolen
Original Assignee
Univ New York
PureTech Health LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66246040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202003652Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ New York, PureTech Health LLC filed Critical Univ New York
Publication of SG11202003652QA publication Critical patent/SG11202003652QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
SG11202003652QA 2017-10-27 2018-10-29 Anti-galectin-9 antibodies and uses thereof SG11202003652QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762578111P 2017-10-27 2017-10-27
US201862665175P 2018-05-01 2018-05-01
US201862736317P 2018-09-25 2018-09-25
PCT/US2018/058028 WO2019084553A1 (fr) 2017-10-27 2018-10-29 Anticorps anti-galectine-9 et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11202003652QA true SG11202003652QA (en) 2020-05-28

Family

ID=66246040

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003652QA SG11202003652QA (en) 2017-10-27 2018-10-29 Anti-galectin-9 antibodies and uses thereof

Country Status (14)

Country Link
US (5) US10344091B2 (fr)
EP (2) EP4597112A2 (fr)
JP (5) JP6873445B2 (fr)
KR (1) KR102162129B1 (fr)
CN (2) CN111511765B (fr)
AU (3) AU2018355588C1 (fr)
CA (1) CA3080120C (fr)
DK (1) DK3625263T3 (fr)
ES (1) ES3032734T3 (fr)
IL (3) IL312910A (fr)
PT (1) PT3625263T (fr)
SG (1) SG11202003652QA (fr)
WO (1) WO2019084553A1 (fr)
ZA (3) ZA202002246B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6873445B2 (ja) 2017-10-27 2021-05-19 ニューヨーク ユニバーシティ 抗ガレクチン−９抗体及びその使用
CN111256416B (zh) * 2018-11-30 2025-09-09 海尔智家股份有限公司 风冷冰箱
CA3134942A1 (fr) * 2019-03-25 2020-10-01 New York University Anticorps anti-galectine-9 et leurs utilisations
US20220178930A1 (en) * 2019-05-01 2022-06-09 New York University Anti-galectin-9 antibodies and uses thereof
JP2022534433A (ja) * 2019-05-31 2022-07-29 ザ・カウンシル・オブ・ザ・クィーンズランド・インスティテュート・オブ・メディカル・リサーチ 抗ｇａｌ９免疫阻害性結合分子
KR20220016152A (ko) * 2019-05-31 2022-02-08 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 항-gal9 결합분자 활성화
EP3987011A1 (fr) * 2019-06-24 2022-04-27 UPM-Kymmene Corporation Composition de cellules transplantables comprenant des cellules eucaryotes dans un hydrogel de cellulose nanofibrillaire, son procédé de préparation et utilisation de cellulose nanofibrillaire
US20220242955A1 (en) * 2019-07-11 2022-08-04 Dana-Farber Cancer Institute, Inc. Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia
EP4007640A4 (fr) * 2019-08-01 2023-10-04 New York University Polythérapie anticancéreuse d'anticorps anti-galectine-9 et d'agents chimiothérapeutiques
EP4013791A4 (fr) * 2019-08-14 2024-01-24 Modmab Therapeutics Inc. Anticorps se liant à des protéines lrp5 et leurs procédés d'utilisation
CN115210261B (zh) * 2020-01-07 2025-07-18 高诚生物医药公司 抗半乳糖凝集素-9抗体及其用途
WO2022020745A1 (fr) * 2020-07-23 2022-01-27 Emory University Agents de liaison spécifiques de la galectine-9 destinés à être utilisés dans le traitement du cancer
CA3188068A1 (fr) * 2020-08-04 2022-02-10 Bryan Glaser Agents de liaison multispecifiques et leurs utilisations
WO2022031695A1 (fr) * 2020-08-04 2022-02-10 Exelixis, Inc. Agents de liaison à pd-l1 et leurs utilisations
CN116507639A (zh) * 2020-08-04 2023-07-28 埃克塞里艾克西斯公司 Cd47结合剂及其用途
WO2022093841A1 (fr) * 2020-10-26 2022-05-05 Puretech Lyt, Inc. Anticorps anti-galectine-9 et leurs utilisations dans le traitement de mélanome oculaire
US20240043543A1 (en) * 2020-11-20 2024-02-08 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
CA3209741A1 (fr) * 2021-02-26 2022-09-01 Shohei Koide Compositions et methodes comprenant des anticorps qui se lient a des conjugues peptidiques covalents
WO2022232653A1 (fr) * 2021-04-30 2022-11-03 Puretech Lyt, Inc. Combinaison d'anticorps anti-galectine-9 et d'agents chimiothérapeutiques destinée à être utilisée dans le traitement du cancer
EP4351736A4 (fr) * 2021-06-11 2025-08-27 Univ California Anticorps qui stimulent la cytotoxicité médiée par les cellules nk
EP4413048A2 (fr) * 2021-10-06 2024-08-14 The University of Chicago Polypeptides ciblant la survivine pour la détection et le traitement du cancer
WO2023112454A1 (fr) * 2021-12-16 2023-06-22 学校法人東京理科大学 Suppresseur de tumeur intestinale, inhibiteur de production de pge2 et promoteur de production d'il-22bp
WO2023245021A2 (fr) * 2022-06-14 2023-12-21 Invenra Inc. Agents de liaison multispécifiques qui ciblent cd25 et/ou ctla4 et leurs utilisations
AU2023301056A1 (en) * 2022-06-29 2025-01-16 Puretech Lyt, Inc. Treatment of hematological malignancies with antibodies inhibiting galectin-9
US20240277122A1 (en) * 2023-02-16 2024-08-22 Dongguan Casekey Industry Co., Ltd Card fixation assembly for card holder and card holder
WO2024258870A2 (fr) 2023-06-12 2024-12-19 Amgen Inc. Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine
WO2025014933A1 (fr) * 2023-07-10 2025-01-16 Northwestern University Ciblage de tim-3 dans un gliome induit par mapk
WO2025085792A1 (fr) * 2023-10-19 2025-04-24 Puretech Lyt, Inc. Traitement de malignités hématologiques avec des anticorps inhibant la galectine-9
WO2025129249A1 (fr) * 2023-12-22 2025-06-26 Commonwealth Scientific And Industrial Research Organisation Identification de fonctionnalité de séquence

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
WO1990007936A1 (fr) 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
EP1645635A3 (fr) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Retrovirus recombinants défectifs pour la réplication exprimant un palliatif
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (fr) 1991-04-10 1992-10-29 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (fr) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (fr) 1992-06-08 1995-11-22 Univ California Procedes et compositions permettant de cibler des tissus specifiques.
WO1993025698A1 (fr) 1992-06-10 1993-12-23 The United States Government As Represented By The Particules vecteurs resistantes a l'inactivation par le serum humain
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (fr) 1992-12-03 2002-05-29 Genzyme Corporation Vecteurs pseudo-adenoviraux pour la thérapie génique des hémophilies
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ES2188612T3 (es) 1993-04-22 2003-07-01 Skyepharma Inc Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso.
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
CA2158937C (fr) 1993-09-15 2006-01-03 Thomas W. Dubensky, Jr. Vecteurs d'alphavirus recombinant
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
CN1099868C (zh) 1993-11-16 2003-01-29 斯卡法玛公司 具有控制释放活性成分作用的囊
EP0772689B1 (fr) 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Vecteurs retroviraux a taux de recombinaison reduit
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997042338A1 (fr) 1996-05-06 1997-11-13 Chiron Corporation Vecteurs retroviraux sans croisement
KR100566859B1 (ko) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Ｒｎａ-단백질 융합물을 이용한 단백질의 선별
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1158997A2 (fr) 1999-03-09 2001-12-05 University Of Southern California Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
AU2002214256B2 (en) 2000-11-01 2007-07-12 Galpharma Co., Ltd. Agent for detecting cancer's ability to metastasize
ES2327905T3 (es) 2001-10-01 2009-11-05 Dyax Corp. Vectores de presentacion eucariotas multi-cadena y usos de los mismos.
EP1586325A1 (fr) * 2003-01-24 2005-10-19 Galpharma Co., Ltd. Medicaments contenant galectine 9
JP2004244411A (ja) * 2003-01-24 2004-09-02 Galpharma Co Ltd ガレクチン９含有医薬
EP2591786B1 (fr) 2003-10-16 2017-04-12 Cancure Limited Compositions immunomodulatrices et leurs utilisations
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
WO2007064919A2 (fr) 2005-12-02 2007-06-07 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
US8133488B2 (en) 2008-01-18 2012-03-13 Genentech, Inc. Methods and compositions for targeting polyubiquitin
ES2337224B1 (es) 2008-06-11 2011-02-17 Consejo Superior De Investigaciones Cientificas (Csic) (40%) Anticuerpo anti-dectin-1 humano, hibridoma productor de dicho anticuerpo y sus aplicaciones.
KR20110052642A (ko) 2008-07-18 2011-05-18 오라제닉스, 인코포레이티드 결장직장암의 검출 및 치료를 위한 조성물
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8772457B2 (en) 2010-11-10 2014-07-08 Genentech, Inc. BACE1 antibodies
WO2012077811A1 (fr) 2010-12-09 2012-06-14 株式会社ガルファーマ Cellule de sécrétion de la galectine-9, son procédé de production, et son utilisation
US20140234320A1 (en) 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
US20140378531A1 (en) 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
WO2015035112A1 (fr) 2013-09-05 2015-03-12 The Johns Hopkins University Thérapie anticancéreuse par l'intermédiaire d'une combinaison de modulation épigénétique et modulation immunitaire
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
FR3021970B1 (fr) * 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
CA2954678A1 (fr) 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Immunotherapie par galectine
CN113929782B (zh) 2014-09-16 2024-06-21 依奈特制药公司 对淋巴细胞中抑制途径的中和
US10640549B2 (en) 2014-10-17 2020-05-05 University Of Virginia Patent Foundation Recombinant antibodies that recognize the C-terminal domains of Ebola virus nucleoprotein
CA2966040A1 (fr) 2014-11-04 2016-05-12 Dana-Farber Cancer Institute, Inc. Biomarqueurs d'anticorps anti-galectine predictifs d'un checkpoint anti-immunitaire et de reponses d'anti-angiogenese
US20160209425A1 (en) 2015-01-16 2016-07-21 New York University Use of dectin-1 activators for treatment of liver disorders
US10294294B2 (en) 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
WO2017202962A1 (fr) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement du cancer du poumon non à petites cellules (cbnpc) qui coexiste avec la bronchopneumopathie chronique obstructive (bpco)
WO2018023113A1 (fr) 2016-07-29 2018-02-01 New York University Traitement d'une tumeur solide par ciblage de signalisation de dectine 1
CA3034105A1 (fr) 2016-09-23 2018-03-29 Csl Limited Proteines de liaison au facteur de coagulation et leurs utilisations
JP6873445B2 (ja) * 2017-10-27 2021-05-19 ニューヨーク ユニバーシティ 抗ガレクチン−９抗体及びその使用
EP3820480A4 (fr) 2018-07-11 2022-03-09 Arrys Therapeutics, Inc. Composés polymorphes et leurs utilisations
CA3134942A1 (fr) 2019-03-25 2020-10-01 New York University Anticorps anti-galectine-9 et leurs utilisations
US20220178930A1 (en) 2019-05-01 2022-06-09 New York University Anti-galectin-9 antibodies and uses thereof

Also Published As

Publication number Publication date
US20200010551A1 (en) 2020-01-09
PT3625263T (pt) 2025-06-20
IL280648B2 (en) 2024-10-01
US20220340666A1 (en) 2022-10-27
JP2021153585A (ja) 2021-10-07
ZA202303412B (en) 2024-09-25
CN115261392B (zh) 2025-05-13
AU2020294364B2 (en) 2023-09-21
US10344091B2 (en) 2019-07-09
CA3080120A1 (fr) 2019-05-02
CN111511765A (zh) 2020-08-07
US10450374B2 (en) 2019-10-22
JP7092317B2 (ja) 2022-06-28
JP2024133590A (ja) 2024-10-02
IL280648A (en) 2021-03-25
EP3625263B8 (fr) 2025-05-28
EP3625263A4 (fr) 2021-05-05
JP2021501120A (ja) 2021-01-14
KR102162129B1 (ko) 2020-10-06
US11629191B2 (en) 2023-04-18
AU2018355588C1 (en) 2023-04-27
JP7523084B2 (ja) 2024-07-26
US20220332830A1 (en) 2022-10-20
JP2023116789A (ja) 2023-08-22
ZA202002246B (en) 2025-04-30
CN111511765B (zh) 2022-05-27
IL280648B1 (en) 2024-06-01
AU2018355588B2 (en) 2020-10-15
CA3080120C (fr) 2023-11-21
IL274152A (en) 2020-06-30
WO2019084553A1 (fr) 2019-05-02
EP3625263A1 (fr) 2020-03-25
ES3032734T3 (en) 2025-07-24
EP4597112A2 (fr) 2025-08-06
NZ764590A (en) 2020-12-18
US20190256604A1 (en) 2019-08-22
IL312910A (en) 2024-07-01
EP3625263B1 (fr) 2025-04-09
AU2020294364A1 (en) 2021-02-18
AU2023285898A1 (en) 2024-01-18
KR102162129B9 (ko) 2023-02-08
CN115261392A (zh) 2022-11-01
IL274152B (en) 2021-02-28
JP6873445B2 (ja) 2021-05-19
AU2018355588A1 (en) 2020-06-11
ZA202102905B (en) 2023-04-26
US20190127472A1 (en) 2019-05-02
KR20200064150A (ko) 2020-06-05
JP7307443B2 (ja) 2023-07-12
DK3625263T3 (da) 2025-06-30
US11414492B2 (en) 2022-08-16
JP2022116325A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
IL324062A (en) Anti-CD73 antibodies and their uses
ZA202102905B (en) Anti-galectin-9 antibodies and uses thereof
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL276950B1 (en) Anti-CD73 antibodies and their uses
IL266738A (en) Novel antibodies and their uses
IL268206A (en) Antibodies directed against bcma and their use
IL264970A (en) Anti-tim-3 antibodies and their use
IL269134A (en) Antibodies against PAR2 and their use
SG11201808632YA (en) Anti-pacap antibodies and uses thereof
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL273157A (en) Antibodies specific to AXL and their uses
IL272476A (en) Anti-Apelin antibodies and their uses
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL266082A (en) Anti-chikv antibodies and their use
IL266049A (en) Antibodies against o1 and their uses
IL274202A (en) Antibodies against Glyco-Moc1 and uses thereof
IL264417A (en) Anti-o2 antibodies and their uses
GB201712032D0 (en) Antibodies and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
SG11202003585VA (en) Anti-vista antibody and use thereof